title: Trastuzumab: unusual responses and toxicities.
abstract: Trastuzumab has become the standard of care in the management of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancers, both in the metastatic and adjuvant setting. Emerging data show continued efficacy of the drug even after disease progression in combination with chemotherapy. While cardiotoxicity is well recognized with trastuzumab, unusual pulmonary toxicities are becoming apparent. Cases that reflect the unusual efficacy and unusual toxicity of trastuzumab are reported.
authors: Department of Medical Oncology, First floor, Charing Cross Hospital, Fulham Palace Road, London, UK. e.ahamed@imperial.ac.uk
authors: Eliyaz
authors: E
authors: Ahamed
authors: Francesco A
authors: FA
authors: Mauri
authors: Grant
authors: G
authors: Pakter
authors: Adrian
authors: A
authors: Lim
authors: Justin
authors: J
authors: Stebbing
mesh_terms: D000911:Antibodies, Monoclonal / Q000633:toxicity*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008168:Lung / Q000187:drug effects*; D008875:Middle Aged; D017239:Paclitaxel / Q000494:pharmacology; D011014:Pneumonia / Q000139:chemically induced; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human